skip to content

Wellcome-MRC Cambridge Stem Cell Institute


Dr Daniel Hodson

Deciphering the genomics of B cell lymphomas


Laboratory: Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre

Departmental Affiliation: Haematology



Daniel Hodson studied Medicine at Cambridge University and then clinical medicine at Oxford University. He subsequently trained as a clinical haematologist with a special interest in lymphoid malignancies. During his haematology training he undertook a PhD in molecular immunology at the Babraham Institute in Cambridge under the supervision of Dr Martin Turner, where he studied the contribution of post-transcriptional regulation to the normal lymphocyte development. In 2010 he moved to the National Cancer Institute, USA, as a post-doctoral fellow in the lab of Dr Lou Staudt, where he developed expertise in the application of functional genomics to the study of B cell lymphomas. In 2015 he returned to Cambridge as a Medical Research Council Clinician Scientist and group leader in the SCI and the Department of Haematology. In 2021 he was awarded a CRUK Senior Cancer Research Fellowship. His group researches the molecular mechanisms that underlie lymphomagenesis. Dr Hodson also holds an honorary consultant contract in the Haematology Department at Cambridge University NHS Hospitals Trust.



CRUK, Kay Kendal Leukaemia Fund, Addenbrooke's Charitable Trust, The Evelyn Trust, MRC


The unique and dangerous life of the B cell



Normal B lymphocytes progress through a series of developmental stages that begin with the haematopoietic stem cell. Progression through each of these stages is tightly controlled at both the transcriptional and post-transcriptional levels. Genetic alterations and mutations, which can occur at any stage from the haematopoietic stem cell to the post-germinal centre B cell, can lead to loss of this normal regulation and subsequently to the development of lymphoid malignancies such as non-Hodgkin Lymphoma (NHL), the 6th commonest form of human cancer. Understanding how these genetic alterations corrupt cell fate choices at each stage of lymphocyte development will be the key to identifying cellular pathways that can be therapeutically targeted. My group has developed novel cell culture models to study the effects of introducing these genetic alterations into healthy human B cells. In particular, we are interested to study how these genetic alterations lead to the transformation of normal B cells into malignant lymphoma cells. We use a variety of techniques including exome and RNA sequencing, ctDNA analysis, ribosome profiling, iCLIP, single cell sequencing, CRISPR, and xenografts to identify the mechanistic contribution of these mutations to lymphomagenesis and the implications this has for the treatment and monitoring of patients.   


Hodson Group photo



Key Publications

  • Gong C, Krupka JA, Gao J, Grigoropoulos NF, Giotopoulos G, Asby R, Screen M, Usheva Z, Cucco F, Barrans S, Painter D, Zaini NBM, Haupl B, Bornelöv S, Ruiz De Los Mozos I, Meng W, Zhou P, Blain AE, Forde S, Matthews J, Khim Tan MG, Burke GAA, Sze SK, Beer P, Burton C, Campbell P, Rand V, Turner SD, Ule J, Roman E, Tooze R, Oellerich T, Huntly BJ, Turner M, Du MQ, Samarajiwa SA, Hodson DJ. Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Mol Cell. 2021 Oct 7;81(19):4059-4075. PMID: 34437837

The Hodson Group

Hodson Group members:

Vibhuti Aggarwal
Hannah Bilboe
Sophie Brocklesby

Natasha Helen Cutmore
Miriam Di Re
Rachel Fenner 
Chun (Jade) Gong
Kaiyue Helian
Ross Jackson
Joanna Krupka
Ilias Moutsopoulos

Galina Shevchenko
Eloise Whittle
Yuran Wang